KRBP Projected Dividend Yield

Kiromic BioPharma Inc ( OTCBB : KRBP )

Kiromic BioPharma is an artificial intelligence driven, end-to-end Chimeric Antigen Receptor T cell and gene therapy company. Co.'s Procel, Isocel, and Deltacel platforms consist of allogeneic cell therapy product candidates that are in the preclinical development stage. Co.'s Procel product candidate consists of engineered GDTs that target PD-L1. Co.'s Isocel product candidate consists of engineered Gamma Delta T cells that target Mesothelin Isoform 2 positive tumors. Co.'s Deltacel product candidate consists of non-engineered GDTs that have been expanded and activated ex- vivo through a process, and are used to treat solid tumors regardless of the specific tumor antigen expression.

20 YEAR PERFORMANCE RESULTS